AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 78 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $43,500 | -35.5% | 150,000 | 0.0% | 0.00% | -50.0% |
Q4 2022 | $67,485 | +169.9% | 150,000 | +208.4% | 0.00% | +100.0% |
Q2 2022 | $25,000 | -91.2% | 48,643 | -60.5% | 0.00% | -80.0% |
Q1 2022 | $283,000 | -47.0% | 123,000 | +7.4% | 0.01% | -58.3% |
Q1 2020 | $534,000 | -31.8% | 114,500 | +11.7% | 0.01% | +9.1% |
Q4 2019 | $783,000 | -0.6% | 102,500 | 0.0% | 0.01% | 0.0% |
Q3 2019 | $788,000 | +12.3% | 102,500 | 0.0% | 0.01% | +22.2% |
Q2 2019 | $702,000 | -14.9% | 102,500 | 0.0% | 0.01% | -10.0% |
Q1 2019 | $825,000 | +7.4% | 102,500 | 0.0% | 0.01% | 0.0% |
Q4 2018 | $768,000 | -21.7% | 102,500 | 0.0% | 0.01% | 0.0% |
Q3 2018 | $981,000 | -7.3% | 102,500 | +2.5% | 0.01% | -9.1% |
Q2 2018 | $1,058,000 | +6.7% | 100,000 | 0.0% | 0.01% | 0.0% |
Q1 2018 | $992,000 | +83.4% | 100,000 | 0.0% | 0.01% | +83.3% |
Q4 2017 | $541,000 | +14.1% | 100,000 | 0.0% | 0.01% | +20.0% |
Q3 2017 | $474,000 | +23.4% | 100,000 | 0.0% | 0.01% | 0.0% |
Q2 2017 | $384,000 | – | 100,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Yu Fan | 112,044 | $532,000 | 6.17% |
Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |